Item 5.02  Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As discussed below in Item 5.07, Travere Therapeutics, Inc. (the "Company") held
its 2021 Annual Meeting of Stockholders (the "Annual Meeting") at which the
Company's stockholders approved the Company's 2018 Equity Incentive Plan, as
amended (the "2018 Plan"), to, among other items, increase the number of shares
of common stock authorized for issuance thereunder by 3,200,000 shares. A
summary of the material terms of the 2018 Plan is set forth in the Company's
definitive proxy statement for the Annual Meeting filed with the Securities and
Exchange Commission on April 16, 2021. That summary is qualified in its entirety
by reference to the text of the 2018 Plan, which is filed as Exhibit 99.1 hereto
and incorporated herein by reference.


Item 5.03  Amendment to Articles of Incorporation or Bylaws; Fiscal Year.
As discussed below in Item 5.07, the Company's stockholders approved a
Certificate of Amendment ("Certificate of Amendment") to the Company's
Certificate of Incorporation to increase the number of shares of common stock
authorized for issuance thereunder by 100,000,000 shares. Effective May 18,
2021, the Certificate of Amendment was filed with the Secretary of State of the
State of Delaware. The Certificate of Amendment is filed as Exhibit 3.1 hereto
and is incorporated herein by reference.


Item 5.07 Submission of Matters to a Vote of Security Holders.
On May 14, 2021, the Company held the Annual Meeting. As of March 23, 2021, the
record date for the Annual Meeting, 60,435,730 shares of common stock were
outstanding and entitled to vote at the Annual Meeting. At the Annual Meeting,
54,357,789 shares of common stock were present in person or represented by proxy
for the five proposals summarized below.
Proposal 1: Election of Directors
The Company's stockholders elected the ten persons listed below to serve until
the Company's 2022 Annual Meeting of Stockholders. The final voting results are
as follows:
                                  Votes For        Votes Withheld         Broker Non-Votes
    Stephen Aselage               50,094,998          2,249,225              2,013,566

    Roy D. Baynes, M.D., Ph.D.    51,245,571          1,098,652            

 2,013,566
    Suzanna Bruhn, Ph.D.          52,215,642           128,581               2,013,566
    Timothy Coughlin              51,571,086           773,137               2,013,566
    Eric Dube, Ph.D.              52,281,622           62,601                2,013,566
    Gary Lyons                    37,604,728         14,739,495              2,013,566
    Jeffrey Meckler               51,294,587          1,049,636              2,013,566
    John A. Orwin                 38,923,225         13,420,998              2,013,566
    Sandra Poole                  52,044,750           299,473               2,013,566
    Ron Squarer                   52,214,745           129,478               2,013,566


Proposal 2: Approval of an Amendment to the Company's Certificate of
Incorporation, as amended
The Company's stockholders approved an amendment to the Company's Certificate of
Incorporation, as amended, to increase the authorized number of shares of common
stock from 100,000,000 to 200,000,000. The final voting results are as follows:
Votes For                 52,270,724
Votes Against             2,084,629
Abstentions                 2,434
Broker Non-Votes              -


Proposal 3: Approval of the Company's 2018 Equity Incentive Plan, as amended
The Company's stockholders approved the 2018 Plan, as amended, to increase the
number of shares of common stock authorized for issuance thereunder by
3,200,000. The final voting results are as follows:

--------------------------------------------------------------------------------


                         Votes For                 47,159,206
                         Votes Against             5,142,241
                         Abstentions                 42,776
                         Broker Non-Votes          2,013,566


Proposal 4: Approval, on an advisory basis, of the compensation of the Company's
named executive officers
The Company's stockholders approved, on an advisory basis, the compensation of
the Company's named executive officers. The final voting results are as follows:
                         Votes For                 51,280,405
                         Votes Against              973,713
                         Abstentions                 90,105
                         Broker Non-Votes          2,013,566


Proposal 5: Ratification of the Selection of Independent Registered Public
Accounting Firm
The Company's stockholders ratified the selection by the Audit Committee of BDO
USA, LLP as the Company's independent registered public accounting firm for the
fiscal year ending December 31, 2021. The final voting results are as follows:
                         Votes For                 54,288,455
                         Votes Against               28,440
                         Abstentions                 40,894
                         Broker Non-Votes              -


Item 9.01  Financial Statements and Exhibits.
(d) Exhibits
             Certificate of Amendment to the Registrant's Certificate of

Incorporation,


3.1        effective May 18, 2021
99.1         Travere Therapeutics    , Inc. 2018 Equity Incentive Plan, as amended.
104        Cover Page Interactive Data File (embedded within the Inline XBRL document).







--------------------------------------------------------------------------------

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TRAVERE THERAPEUTICS, INC.



Dated: May 18, 2021                                                    By:

/s/ Elizabeth E. Reed

Name: Elizabeth E. Reed

Senior Vice President, General

Title: Counsel and Secretary

© Edgar Online, source Glimpses